Jacobson Pharma (02633) announced that on April 1, 2026, a consultant acting on behalf of its indirect wholly-owned subsidiary, Ching Mei Drug Company, signed a letter of acceptance to confirm the tender submitted by the contractor for providing specific infrastructure development and specialized facility works at the Tai Po plant. The total contract value is HKD 607.2 million.

In 2025, Ching Mei Drug Company acquired the dedicated pharmaceutical facility, the Tai Po plant, located at 7 Tai Hei Street, Tai Po Industrial Estate, Tai Po, New Territories, Hong Kong, China. Ching Mei Drug Company plans to establish ten new intelligent pharmaceutical production lines at this facility, covering sterile eye drops, solid dosage forms, and oral liquid medications.

The consultant assisted Ching Mei Drug Company in evaluating the submitted tenders through an open bidding process and provided recommendations regarding the bids submitted by contractors for the specific infrastructure development and specialized facility works.

The Group remains committed to advancing its strategic focus in dedicated pharmaceuticals and smart manufacturing. Supported by the Hong Kong government's New Industrialisation Acceleration Scheme, the Tai Po facility will become a cornerstone of this strategy. The facility will utilize AI and robotics-driven production lines for sterile, solid, and oral liquid dosage forms, aiming to support efficient, high-quality production while meeting local and global healthcare needs.

The anticipated transaction is expected to bring significant benefits to the Group. Strategically, this move reinforces the company's leading position in the pharmaceutical industry and aligns with Hong Kong's vision of becoming an advanced industrial hub. In terms of innovation, the facility leverages advanced technology and collaborative capabilities to enhance production efficiency, quality, and competitiveness, supporting the Group's long-term growth objectives.